[Qualitative and quantitative parameters for prognosis in renal carcinoma in early and advanced stages].
OBJECTIVE
A minority of stage I renal cell cancers have a bad prognosis, a minority of those in stage II-IV may behave favorably. Are there parameters which characterize such cases? In this study, a number of qualitative and quantitative parameters are used to detect differences between cases with at least 9 years of survival and those with a survival of less than 9 years.


METHODS
133 cases of renal cell cancer were subdivided into stage subgroups: Robson's I; Robson's II-IV. The following data and parameters were registered and/or measured: sex, stage, tumor size, histological type, mean nuclear profile area (mA) and pleomorphism (standard deviation of mean nuclear profile area--SDA) nuclear grade (NG) and combined nuclear grade (CNG), DNA index, cell proliferation, as determined by mitotic index (MI), per cent of PCNA positive cells (PCNA + cells %), per cent of S-phase cells (SP cells %), p53 and EGFR expression, intratumoral T lymphocytes.


RESULTS
Older patients have a worse prognosis independently of the stage. Stage is the most discriminant qualitative parameter; tumor dimensions and both nuclear and combined nuclear grade are important too. Mean nuclear profile area and pleomorphism are also discriminant, while no prognostic value of histological type is shown and histology is not related to other parameters. Higher DNA index characterizes cases with worse prognosis, as well as MI, SP cells %, PCNA + cells %, and EGFR expression. No significant differences are detected for p53 expression and lymphoid infiltrates. A minority of patients with stage I tumors die within 9 years of diagnosis. They are older than survivors with the same stage, their tumors have larger nuclear area and greater pleomorphism, and are more frequently aneuploid with higher DNA index. A minority of patients with stage II-IV tumors survive at least 9 years from the time of diagnosis. They are younger than non-survivors in the same stages and have lower MI and PCNA positivity in the tumors, while other parameters are not discriminant.
Del Vecchio
M T
MT
Sezione di Urologia, Azienda Ospedaliera Senese, Siena.
Spina
D
D
Lazzi
S
S
Bruni
A
A
Funtò
I
I
Mattei
F M
FM
Fornaini
M
M
Luzi
P
P
Tosi
P
P
D000951:Antigens, Neoplasm / Q000032:analysis; D015415:Biomarkers; D014408:Biomarkers, Tumor; D002292:Carcinoma, Renal Cell / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D002467:Cell Nucleus / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D008297:Male; D008940:Mitotic Index; D009363:Neoplasm Proteins / Q000032:analysis; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D016196:S Phase; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D000951:Antigens, Neoplasm; D015415:Biomarkers; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors
Parametri qualitativi e quantitativi per la prognosi del carcinoma renale in stadio precoce ed avanzato.